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Edited by Lukas HuberAbstract Our previous study reveals that connexin (Cx) 43 is
targeted by ACh to prevent lethal arrhythmia. Granulocyte col-
ony-stimulating factor (G-CSF), used against ischemic heart
failure, may be another candidate, however, with unknown mech-
anisms. Therefore, we investigated the cellular eﬀects of G-CSF.
G-CSF activated the Wnt and Jak2 signals in cardiomyocytes,
and up-regulated Cx43 protein and phosphorylation levels. In
addition, G-CSF enhanced the localization of Cx43, b-catenin
and cadherin on the plasma membrane. G-CSF inhibited the
reduction of Cx43 by enhancing Cx43 anchoring and sustained
the cell–cell communication during hypoxia. Consequently, G-
CSF suppressed ventricular arrhythmia induced by myocardial
infarction. As a result, G-CSF could be used as a therapeutic
tool for arrhythmia.
 2007 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
Keywords: Granulocyte-colony stimulating factor; Connexin;
Hypoxia; Cadherin; b-Catenin; Gap junction1. Introduction
Treatment of patients with chronic heart failure has been an
area of great interests, because the prognosis in heart failure
remains to be poor despite novel therapeutic modalities.
Among various causes in heart failure, myocardial infarction
is the most common and novel therapeutic modalities for heart
failure are much needed. Researchers have recently focused on
the novel therapeutic ﬁeld of cardiac regeneration induced by
transplantation of embryonic stem cells, mesenchymal cells,
bone marrow cells, or myoblasts and the administration of
granulocyte-colony stimulating factor (G-CSF).
Previous studies have shown that cardiomyocytes are eﬃ-
ciently and remarkably transdiﬀerentiated from transplanted
progenitor cells derived from bone marrow cells. However, re-
cent studies have revealed that the regeneration rate from pro-
genitor cells to cardiomyocytes is quite low and they
frequently fuse with resident cardiomyocytes, and that the ac-
tual transdiﬀerentiation rate is extremely low not enough to im-*Corresponding author. Fax: +81 (0) 88 880 2310.
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if transdiﬀerentiation alone could be involved in the situation
[1–4]. Surprisingly, however, such treatments in fact improve
the function by unknown mechanisms. Even with treatments
using G-CSF, it has been also reported that the transdiﬀerenti-
ation rate is quite low, but that cardiac function is markedly im-
proved [5,6]. Recently, it has been reported that G-CSF has a
direct eﬀect on cardiomyocytes through the receptor responsible
for cardiac hypertrophy and inhibits both apoptosis and remod-
eling in the failing heart following myocardial infarction [7].
It is important to consider two of key factors aﬀecting sur-
vival rate in patients with chronic heart failure, i.e., suppression
of the progression of cardiac remodeling and suppression of the
fatal arrhythmia. As an elegant previous study demonstrates,
G-CSF inhibits cardiac remodeling, resulting in survival rate
improvement [7]. However, it remains to be investigated
whether G-CSF has an anti-arrhythmia eﬀect, because the
study referred to did not investigate this in detail. Furthermore,
there are no reports that reveal the detailed molecular mecha-
nisms of the anti-arrhythmia eﬀect of G-CSF.
Connexin (Cx) 43, a component of the gap junction complex,
has recently been reported to be involved in modulating
arrhythmia. The survival of Cx43 knockout mice was lower
than that of wild-type mice because of greater susceptibility
to lethal arrhythmia, including ventricular tachycardia and
ﬁbrillation. This suggests that Cx43 plays a crucial role in mod-
ulating arrhythmia [8–11]. We recently demonstrated in rats
that acetylcholine (ACh) activates the function of gap junctions
by sustaining the Cx43 protein level leading to inhibition of the
lethal arrhythmia that follows myocardial infarction [12].
In the present study, we assessed the hypothesis that G-CSF
has an anti-arrhythmia eﬀect apart from its anti-apoptotic ef-
fect, through the sustainable localization of Cx43 on the plas-
ma membrane, leading to an additive contribution to the
increased survival rate following the ischemic heart diseases.2. Materials and methods
2.1. Cell culture
To examine the eﬀect of G-CSF on cardiomyocytes, we used pri-
mary cardiomyocytes isolated from neonatal rats and H9c2 cells.
H9c2 cells are frequently used to investigate signal transduction and
channels instead of rat primary cardiomyocytes. H9c2 cells have
an advantage to be more eﬃciently gene-transferred than primary
cardiomyocytes, therefore, in the present study H9c2 cells were usedblished by Elsevier B.V. All rights reserved.
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containing 10% FBS and antibiotics. Rat primary cardiomyocytes
were isolated from 2- to 3-day-old neonatal Wistar rats and incubated
in DMEM/Ham F-12 containing 10% FBS and ITS supplement.
HEK293 cells were used in gene transfection studies; they were cul-
tured in DMEM containing 10% FBS.2.2. Western blot analysis
Rat primary cardiomyocytes or H9c2 cells were treated with 10 ng/
ml of G-CSF to evaluate their protein expression level under normoxic
or hypoxic conditions with 1 mM of cobalt chloride (CoCl2) or an oxy-
gen concentration of 1%. In the case of hypoxia, cardiomyocytes were
pretreated with G-CSF 24 h before hypoxia, followed by 12 h of hyp-
oxic treatment. Cell lysates were mixed with a sample buﬀer, fraction-
ated by SDS–PAGE and transferred onto membranes. The membranes
were incubated with polyclonal primary antibodies against G-CSF
receptor, phospho-JAK2 (Santa Cruz Biotechnology, Santa Cruz,
CA), b-catenin (Cell Signaling Technology, Beverly, MA, USA) or
Cx43 (ZYMED Laboratories Inc., South San Francisco, CA), and
monoclonal antibodies against a-tubulin (Lab Vision, Fremont, CA),
phospho-Akt (Cell Signaling Technology) or pan-cadherin (Sigma
Chemical Co., St. Louis, MO). They were then reacted with an
HRP-conjugated secondary antibody (BD Transduction Laboratories,
San Diego, CA, USA, and Promega, Madison, WI). Positive signals
were detected with an enhanced chemiluminescence system (Amer-
sham, Piscataway, NJ). In each study, experiments were performed
in duplicate and repeated four or ﬁve times (n = 4 or 5). Only represen-
tative data alone are shown.
2.3. MTT activity assay
To evaluate the eﬀects of hypoxia on the mitochondrial function of
cardiomyocytes, we measured the reduction activity of 3-(4,5-dimethyl-
thiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) in cardiomyo-
cytes under hypoxic conditions in the presence or absence of G-CSF.
The cells were pretreated with 10 ng/ml G-CSF for 24 h and then sub-
jected to 12-h hypoxia. One hour before sampling, the MTT reagents
were added to the culture and incubated; and absorbance at 450 nm
was measured (Cell Counting Kit-8; Dojindo, Kumamoto, Japan).2.4. Myocardial infarction in rats
Left ventricular myocardial infarction was induced by left coronary
artery ligation in anesthetized male Wistar rats, which were ventilated
artiﬁcially. G-CSF (5 lg/kg) was administered intraperitoneally 24 h
before coronary ligation. For 30 min after the coronary ligation,
ECG was recorded to evaluate arrhythmia, and blood pressure was
also monitored in rats with or without G-CSF treatment (no treat-
ment, n = 4; G-CSF treatment, n = 7).
2.5. Transfection
To investigate whether G-CSF regulates Wnt signaling, the reporter
vector of TOPﬂash (Upstate Cell Signaling Solutions, Lake Placid,
NY) was used for transfection into H9c2 cells. The reporter vector pos-
sesses three copies of the T-cell factor binding site. H9c2 cells were
transfected together with TOPﬂash vector and SeaPansy vector by
Eﬀectene (Quiagen, Valencia, CA) according to the manufacturer’s
protocol. After 24 h of transfection, G-CSF (10 ng/ml) was added.
Transfected cells were lysed further 24 h later, and the luciferase activ-
ity was evaluated with a dual luciferase activity assay kit from Wako
Chemical (Tokyo, Japan).2.6. Immunocytochemistry
Rat primary cardiomyocytes were ﬁxed with 4% paraformaldehyde
for 10 min and permeabilized with 0.1% Triton X-100 for 10 min.
Then, cells were incubated with 4% skim milk and successively incu-
bated with an anti-Cx43 polyclonal antibody (ZYMED Laboratories
Inc.), anti-b-catenin polyclonal antibody (Cell Signaling Technology)
or anti-pan-cadherin monoclonal antibody (Sigma Chemical Co.), in
1% skim milk at 4 C overnight, followed by FITC or Cy3-conjugated
secondary antibodies (Jackson ImmunoResearch Laboratories, West
Grove, PA) at 4 C overnight. After mounting, imaging of the immu-
noreactivities were examined and obtained with an OLYMPUS FLU-
OVIEW 300 laser-scanning confocal microscope (OLYMPUS, Tokyo,
Japan).2.7. RT-PCR
Total RNA was isolated from primary cardiomyocytes according to
a modiﬁed acid guanidinium–phenol–chloroform method using an
RNA isolation kit (ISOGEN; Nippon Gene, Tokyo, Japan) and was
reverse-transcribed to obtain a ﬁrst-strand cDNA. This ﬁrst-strand
cDNA was ampliﬁed by speciﬁc primers, and the PCR products were
fractionated by electrophoresis.2.8. Functional analysis of gap junctions using a scrape/scratch or
microinjection method
A scrape-loading method was used to introduce macromolecules
into cultured cells by inducing a transient tear in the plasma mem-
brane, thereby allowing sensitive determination of cell–cell communi-
cation. Following treatment with 10 ng/ml G-CSF for 24 h, 1%
Lucifer Yellow was applied to the center of the coverslip, on which
cardiomyocytes were cultured. A 27-gauge needle was used to create
two longitudinal scratches through the cell monolayer. One minute la-
ter, the cardiomyocytes were washed and ﬁnally examined by Axiovert
ﬂuorescence microscopy (Carl Zeiss, Inc.). Lucifer Yellow is transmit-
ted from one cell to another, presumably across patent gap junctions
[13–16]. The area of the dye transferred from the scratched margin
in hypoxia or hypoxia with G-CSF treatment was semiquantiﬁed using
the NIH image system and compared with that in normoxia. In
another dye transfer assay, using a microinjection method, LY was in-
jected electrophoretically via a conventional microelectrode made from
glass capillaries using micromanipulator system (SURUGA SEIKI
Co, Ltd., Shizuoka, Japan). The outer diameter of microelectrodes
was 0.15–0.25 lm. An inward square-pulse current of 100 ms duration
was injected at 2 Hz for 1 min using a voltage pulse generator
(SEN7203, NIHONKONDEN, Tokyo, Japan). In this microinjection,
experiments could not be practically conducted in a hypoxic chamber,
therefore, a chemical hypoxic reagent of CoCl2 (1 mM) was used to in-
duce cellular hypoxia.2.9. Electrophysiological evaluation of the G-CSF eﬀect on
cardiomyocytes during hypoxia using mitochondrial membrane
potential dye
Rat primary cardiomyocytes were pretreated with 10 ng/ml G-CSF
for 24 h, followed by 1% hypoxia for 1 h. During hypoxia, the cardio-
myocytes were incubated with 2 lM di-4-ANEPPS (pyridinium,4-{2-
[6-(dibutylamino)-2-naphthalenyl]ethenyl}-1-(3-sulfopropyl)-hydroxide)
for 15 min followed by washing. In the presence of cytochalasin D
(5 lM), during hypoxic conditions with or without G-CSF, the cardio-
myocytes were observed to evaluate the propagation of action poten-
tials, using an imaging system for opto-electrophysiology, MiCAM02
(Brainvision, Tokyo, Japan).2.10. Densitometry
The Western blotting data were analyzed using Kodak 1D Image
Analysis Software (Eastman Kodak Co., Rochester, NY).
2.11. Statistics
The data are presented as means ± S.E. (standard error). Mean val-
ues between two groups were compared using the unpaired Student’s t-
test. Multiple comparisons of results were assessed by ANOVA for
multiple comparisons of results. Diﬀerences were considered signiﬁcant
at P < 0.05.3. Results
3.1. G-CSF transduces the signal through its receptor in
cardiomyocytes
The expression level of G-CSF receptor (G-CSFR) was
examined by Western blot analysis. As shown in Fig. 1,
G-CSFR was detected in rat primary cardiomyocytes with a
molecular weight of 130 kDa. To investigate whether the
G-CSFR was functional in cardiomyocytes, we evaluated sig-
nal transduction through JAK2 phosphorylation, one of the
major signaling molecules for G-CSFR. As shown in Fig. 1,
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Fig. 1. G-CSF receptor protein expression is detected in rat primary cardiomyocytes and transduces the signal through JAK2 phosphorylation.
G-CSF receptor was expressed in rat primary cardiomyocytes (A), and G-CSF (10 ng/ml) phosphorylated JAK2 within 4 h, one of crucial factors
responsible for cardiac hypertrophy in rat primary cardiomyocytes and H9c2 cells. Representative data are shown from four independent
experiments (n = 4 in each cell) (B). The G-CSF treatment was accompanied by enlargement of cell size (#P < 0.01 vs. control, n = 6), the extent of
which was comparable with that of ET-1 (1 lM) (#P < 0.01 vs. control, n = 6). Bars in the upper panels, 10 lm; lower panels, 20 lm (C).
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myocytes. Likewise, JAK2 was also phosphorylated in H9c2
cells, cell lines of rat ventricular myocytes, by G-CSF suggest-
ing that H9c2 cells are equipped with the similar machinery
responding G-CSF. As a result, along with the JAK2 phos-
phorylation, an important signal responsible for cardiac hyper-
trophy, G-CSF actually increased cell size within 24 h (365.2 ±
22.2%, #P < 0.01 vs. control, n = 6) comparably with 1 lM
ET-1 (287.2 ± 35.3%, #P < 0.01 vs. control, n = 6). A similar
eﬀect was also observed in H9c2 cells (data not shown).
Although a G-CSFR-speciﬁc receptor antagonist is not avail-
able, taken together with the fact that JAK2 is known to be
a G-CSFR-related molecule, it is suggested that G-CSF acts
on cardiomyocytes through its receptor.
3.2. G-CSF has a cell survival eﬀect on cardiomyocytes during
hypoxic condition
To study whether G-CSF has a cell survival eﬀect on rat pri-
mary cardiomyocytes, we ﬁrst examined Akt phosphorylation,
a cell survival signal, in response to G-CSF. As demonstrated
in Fig. 2, Akt was phosphorylated by G-CSF (10 ng/ml) within4 h, suggesting that G-CSF plays a role in transducing a cell
survival signal. To investigate whether G-CSF actually pos-
sesses such a cell-protective eﬀect, cardiomyocytes were treated
with 1 mM CoCl2, a hypoxic reagent, for 8 h following the
24-h G-CSF pretreatment. With CoCl2 alone, cell viability,
which was evaluated with the MTT reduction assay, was mark-
edly reduced in the absence of G-CSF. However, the G-CSF
pretreatment sustained cell viability even in the presence of
CoCl2 (n = 6, P < 0.001 vs. CoCl2) for 8 h. This suggests that
G-CSF has a cell-protective eﬀect.
3.3. G-CSF shows an anti-arrhythmia eﬀect on acute myocardial
infarction
It has been reported that G-CSF has a chronic eﬀect on
myocardial infarcted rats, leading to an increase in the survival
rate of rats with chronic myocardial infarction, and it has been
speculated that this eﬀect probably occurs through inhibition
of cardiac remodeling, i.e. inhibition of death due to chronic
cardiac pump failure. However, the eﬀects of G-CSF on sup-
pression of fetal arrhythmia in the chronic stage were not fully
investigated. Furthermore, an acute eﬀect of G-CSF on the
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Fig. 2. G-CSF induces Akt phosphorylation and protects cardiomyo-
cytes from a hypoxic mimetic. Akt was phosphorylated by G-CSF
(10 ng/ml) with a longer time course. Representative data are shown
from four independent experiments. G-CSF-pretreated cardiomyo-
cytes (24 h) showed comparable cell viability even with 1 mM CoCl2
for 8 h, evaluated by the MTT reduction assay (n = 6).
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was 100% in the non-treated rat. In contrast, G-CSF-treated rats did not sho
expression level in the heart. Representative Western blot data are shown (1–3
CSF also decreased the duration of ventricular tachycardia (10.9 ± 2.3 vs. 5
4824 M. Kuwabara et al. / FEBS Letters 581 (2007) 4821–4830infarcted heart has not yet been profoundly studied, especially
the eﬀect of G-CSF on arrhythmogenesis in acute myocardial
infarction. Therefore, we performed an in vivo study to inves-
tigate whether G-CSF pretreatment has an anti-arrhythmia
eﬀect on the myocardial infarcted heart.
Rats were pretreated or not pretreated with 5 lg/kg G-CSF
24 h before the left coronary artery ligation. Without G-CSF
treatment, all rats suﬀered from ventricular arrhythmia. As
demonstrated in Fig. 3A, a G-CSF-untreated rat abruptly
showed a decrease in blood pressure due to ventricular ﬁbrilla-
tion (VF), however, the treated rat sustained blood pressure
during the entire time course. Especially, VF was usually ob-
served within 30 min after the coronary ligation (100%), with
a lethal episode in some rats because of sustained VF. In con-
trast, the G-CSF-pretreated rats suﬀered less frequently from
ventricular arrhythmia. Speciﬁcally, VF was never detected
in the G-CSF-treated rats (0%). In rats treated with G-CSF,
the phosphorylated forms of Cx43 protein in the hearts was
greatly increased, compared with those non-treated hearts
(Fig. 3A). Furthermore, G-CSF also reduced the other
arrhythmia parameter, the duration of ventricular tachycardia
(VT) (10.9 ± 2.3 vs. 58.7 ± 3.4 sec, P < 0.01). These results sug-
gest that G-CSF is involved in inhibiting arrhythmia induced
by myocardial infarction.B
60
G-CSF
VT
 d
ur
at
io
n 
(x1
03 
m
s
e
c
)
control
(MI alone)
P < 0.01
30
120
100
80
60
40
2000150010005000
Hg)
(msec.)
G-CSF (+)
rylated
Cx43
ia induced by acute myocardial infarction. A representative time course
ts without G-CSF pretreatment, VF occurred in the late phase after
usly attenuated (n = 6). The occurrence of ventricular ﬁbrillation (VF)
w VF (n = 7). Furthermore, G-CSF increased a phosphorylated Cx43
, no treatment; 4–6, G-CSF-treatment) (A). In accordance with this, G-
8.7 ± 3.4 s, P < 0.01) (B).
M. Kuwabara et al. / FEBS Letters 581 (2007) 4821–4830 48253.4. G-CSF activates Wnt signal in cardiomyocytes
To further clarify the anti-arrhythmia mechanism of G-CSF,
we ﬁrst focused on the Wnt signal, which is involved in cell–cell
communication as well as cell survival. Therefore, the Wnt sig-
nal was examined in cardiomyocytes in response to G-CSF. As
shown in Fig. 4A, H9c2 cells were transfected with the TOP-
ﬂash luciferase vector and SeaPansy vector for dual luciferase
evaluation system. Luciferase activity was increased by G-CSF
up to 10.1- and 25.9-fold following the 24- and 36-h treat-
ments, respectively (#P < 0.01 vs. 0 h). In accordance with this
result, b-catenin protein expression was greatly increased by
G-CSF in whole cell lysates from both H9c2 cells and primary
cardiomyocytes (292.6 ± 14.4 %, #P < 0.01 and 437.0 ± 10.3%,
#P < 0.01, respectively) (Fig. 4B). Since b-catenin is known to
be regulated by a negative regulator of Wnt signal GSK-3b,
which phosphorylates b-catenin and accelerates degradation
of the protein, it is suggested that G-CSF activates the Wnt
signal in cardiomyocytes, resulting in inhibition of b-catenin
degradation.
3.5. G-CSF inhibits degradation of Cx43
According to our results, we speculated that G-CSF plays an
important role in inhibiting the degradation of protein other
than b-catenin through Wnt signal activation. Therefore, we
examined whether G-CSF increased the Cx43 protein level.
Cx43 is also known to possess a shorter protein half-life and
rapidly regulated by the protein degradation system.B
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Fig. 4. G-CSF activates the Wnt signal in cardiomyocytes through the incre
TOPﬂash vector, adjusted by a SeaPansy luciferase activity, was increased by 1
luciferase activity was evident within 24 h (#P < 0.01 vs. 0 h). Representative
luciferase activity contributed to elevated b-catenin protein expression (n =
protein expression (#P < 0.01 vs. 0 h in each cell group) (B).Initially, Cx43 mRNA expression level was evaluated by
RT-PCR. As shown in Fig. 5, the Cx43 mRNA level was
not increased by G-CSF. In contrast, the total Cx43 protein le-
vel was markedly increased by G-CSF in rat primary cardio-
myocytes. Speciﬁcally, a Cx43 phosphorylated form, which
was composed of upper two bands designated as P-Cx43 in
Fig. 5, was more increased by G-CSF. The lower band desig-
nated as a non-phosphorylated band (N-Cx43 in Fig. 5) was
also up-regulated by G-CSF.
To further elucidate the eﬀect of G-CSF on the localization
of gap junction components on the cell surface, an immunocy-
tochemical study was conducted using antibodies against b-
catenin, pan-cadherin and Cx43 and it was also investigated
whether the components had any mutual interaction. Such
G-CSF-increased b-catenin signals overlapped, especially on
the plasma membrane, with those of Cx43 (Fig. 6), and it
was colocalized with increased signals of cadherin, which was
also evident by Western blot analysis (Fig. 6), suggesting that
G-CSF increases protein levels of gap junction components,
including b-catenin, cadherin, and Cx43, and that the localiza-
tion of these components on the cytoplasmic membrane is
tightly regulated by G-CSF.
3.6. G-CSF functionally activates the gap junction in primary
cardiomyocytes
To further study whether G-CSF modulates the function of
gap junctions, a dye transfer study was conducted using Luci-24h 36h
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Fig. 5. The Connexin43 (Cx43) protein expression level is increased by G-CSF, independent of the transcriptional regulation, under the normoxic
conditions. The Cx43 mRNA level was not aﬀected by 10 ng/ml G-CSF within 24 h; however, the protein expression level including upper two
phosphorylated forms (P-Cx43) and lower one (N-Cx43) was increased by G-CSF within 24 h (n = 5). In Western blot analysis, Cx43 is known to be
composed of upper bands as phosphorylated forms and lower band as non-phosphorylated one.
Fig. 6. G-CSF increased immunoreactivities of b-catenin, cadherin, and Cx43 and increased their colocalization under normoxic conditions. Primary
cardiomyocytes from G-CSF-treated rats showed more immunoreactivities of b-catenin, cadherin, and Cx43, compared with non-treated
cardiomyocytes, as also shown with increased expression of cadherin in Western blot analysis. These immunoreactivities overlapped especially in the
cytoplasmic membrane. Compared with control, distribution of b-catenin was speciﬁcally detected on cytoplasmic membrane in G-CSF-treated
cardiomyocytes. Representative data from six independent experiments are shown (n = 6). Bars, 20 lm.
4826 M. Kuwabara et al. / FEBS Letters 581 (2007) 4821–4830fer Yellow with a scrape/scratch or microinjection method.
Hypoxia decreased the gap junction function along with reduc-
tion in dye transfer, compared with normoxia, demonstratingthat gap junction was impaired by 1% of hypoxia (Fig. 7A).
However, pretreatment with G-CSF inhibited the reduction
of dye transfer, and the transfer level during hypoxia was sus-
Fig. 7. G-CSF enhances the cell–cell communication as demonstrated by the scrape/scratch and microinjection methods. Lucifer yellow dye was not
eﬃciently transferred during 1% hypoxia, evaluated by a scrape/scratch method (A), and treatment with 1 mM of CoCl2, evaluated by a
microinjection method (B), compared with normoxia. However, G-CSF pretreatment sustained dye transfer at a level similar to that during normoxia
(n = 5) (A, B).
Fig. 8. Propagation of membrane potential in rat primary cardiomyocytes is sustained by G-CSF during hypoxia. The propagation of the action
potential, detected by di-4-ANEPPS, in rat primary cardiomyocytes decreased during hypoxia, with a shorter action potential duration and lower
frequency. However, in G-CSF-pretreated cardiomyocytes the action potential propagated comparably with normoxic cardiomyocytes. Duration
and frequency were not remarkably decreased by hypoxia in G-CSF-treated cardiomyocytes. Representative data from ﬁve independent experiments
are shown (n = 5).
M. Kuwabara et al. / FEBS Letters 581 (2007) 4821–4830 4827tained at a level similar to that in normoxia by G-CSF
(Fig. 7A). A microinjection method also indicated that hypox-
ia induced by 1 mM of CoCl2 decreased dye transfer, resulting
in the dye remaining in the cell. In this microinjection, chemi-
cal hypoxic reagent CoCl2 was used instead of 1% hypoxia, be-
cause microinjection could not be practically performed in a
hypoxic chamber. However, G-CSF treatment resulted in
recovery of cell–cell communication even during hypoxia
(Fig. 7B). This suggests that G-CSF regulates gap junction
to enhance cell–cell communication through the stabilization
of gap junction components to the plasma membrane. This
may contribute to the anti-arrhythmia eﬀect.
To investigate the electrophysiological eﬀects of G-CSF on
gap junctions, the propagation of membrane potential in
cardiomyocytes was evaluated using di-4-ANEPPS (pyridini-
um,4-{2-[6-(dibutylamino)-2-naphthalenyl]ethenyl}-1-(3-sulfo-
propyl)-hydroxide). As demonstrated in Fig. 8, in the absence
of G-CSF, the activation and propagation of the action poten-
tial was dampened by hypoxia. In contrast, in G-CSF-pre-treated cardiomyocytes, activation and propagation of the
membrane potential were sustained even in hypoxia, suggest-
ing that G-CSF sustains gap junction function even during hy-
poxia.
Taken these results together, we suggest that G-CSF inhibits
the impairment of the gap junction function during hypoxia by
sustaining the protein levels of the components in cardiomyo-
cytes. Therefore, the use of G-CSF could lead to an anti-
arrhythmia eﬀect on cardiomyocytes during hypoxia.4. Discussion
In contrast with the previous studies using G-CSF, the pres-
ent study demonstrates a novel function of G-CSF. We dem-
onstrate that G-CSF stabilizes the gap junction complex
through the Wnt signal to sustain its function even under hyp-
oxic conditions. Therefore, we suggest that G-CSF inhibits
impairment of the gap junction function and has the potency
4828 M. Kuwabara et al. / FEBS Letters 581 (2007) 4821–4830to suppress ventricular arrhythmia after acute myocardial
ischemia and may be used as a therapeutic tool.
In the present study, we initially demonstrate that G-CSF
has a direct eﬀect on cardiomyocytes through G-CSFR with
activation of JAK2 signal transduction, as reported in previous
studies [7], and that G-CSF also plays a pivotal role in increas-
ing the protein expression levels of b-catenin and Cx43.
b-Catenin is known to be involved in regulating the gap junc-
tion complex and other membrane-associated molecules
including cadherin. These are also known to be indispensable
for gap junction complex formation [17–21]. In accordance
with this, the Wnt signal is activated by G-CSF, as demon-
strated by TOPﬂash reporter assay. Activation of the Wnt sig-
nal, resulting in increased b-catenin levels, as found in this
study, is also reported to be responsible for cell survival [22–
24]. It also reveals that G-CSF protects cells against chemical
hypoxic stress. The results can be combined to suggest that G-
CSF plays a role in cardioprotection through the survival
pathway of the Wnt signal.
Furthermore, this study reveals a novel G-CSF function
acting through b-catenin. Besides the cell survival signal, G-
CSF increases cell–cell communication by inhibiting Cx43
protein degradation and increasing the cadherin level as
shown in Fig. 6, resulting in increased expression levels of
gap junction components. These eﬀects are conﬁrmed by the
sustained dye transfer in cardiomyocytes even during hypoxia
in the presence of G-CSF alone, as shown in scrape/scratch
and microinjection experiments. These in vitro data are also
conﬁrmed by a rat model of acute myocardial ischemia with
a reduced frequency of ventricular tachycardiac arrhythmia
after G-CSF treatment. Therefore, from the results of the
present study, we suggest that G-CSF has another novel eﬀect
of anti-arrhythmia through the activation of gap junction
function.
Many studies have been performed on the pathogenesis of
arrhythmia [25–27]. Recently, the impairment of gap junction
function has been focused on as one of the pathogenic fea-
tures [8–11]. Since heterogeneity of conduction velocity is in-
duced by hypoxia through impairment of gap junctions, it is
considered that impairment of gap junctions is responsible
for one of the arrhythmogenic substrates. Speciﬁcally, Cx43
knockout mice are reported to be remarkably susceptible to
ventricular arrhythmia, causing sudden death [9]. In addition,
our recent works have revealed that acetylcholine plays a
pivotal role in sustaining the Cx43 protein level during hy-
poxia and that vagal nerve stimulation inhibits arrhythmia
induced by acute myocardial infarction by sustaining the
Cx43 protein level [12,28]; this suggests that intact gap junc-
tion function is necessary for the inhibition of arrhythmia.
Based on these studies, it is suggested that a drug that in-
creases the Cx43 protein expression level or sustains its
appropriate localization might provide a therapeutic tool
for arrhythmia in addition to currently available anti-
arrhythmia drugs.
The present study suggests a precise mechanism for the reg-
ulation of Cx43 protein level by G-CSF, which activates Wnt
signal, leading to stabilization of the protein localization on
plasma membrane along with other membrane-associated mol-
ecules and to improvement of gap junction function. There are
no studies clearly demonstrating a precise link between G-
CSF, Wnt signal and the anti-arrhythmia eﬀect, therefore,
the present study was performed. However, several previousstudies suggest each link, i.e. Wnt signal and Cx43. The present
results are compatible with the study demonstrating that acti-
vation of the Wnt signal by lithium chloride in cardiomyocytes
causes an increase in the Cx43 protein level [29]. Other studies
also reveal that the activated Wnt signal increases cell aggrega-
tion, which is resistant to agitation, suggesting an increase in
intercellular communication [30,31]. These ﬁndings indicate
that Wnt signal activation accelerates cell–cell interaction
through molecules involved in gap junction formation. Gap
junctions are composed of connexin subtypes and are sup-
ported by the formation of complexes with cadherin and b-
catenin [32,33]. b-catenin is located in the subcytoplasmic
membrane and anchors Cx43 to the membrane [29,30]. It is re-
ported that the Cx43 function is modulated by the total protein
level as well as the phosphorylation level [34] and is also af-
fected by these anchoring molecules. These are tightly associ-
ated with Cx43, resulting in complex formation, and are
essential in maintaining the gap junction function, because
knockout mice, including cadherin knockout mice, show
abnormal gap junction function, causing susceptibility to
arrhythmia [17]. Heterogeneous cadherin knockout mice do
not survive as long as wild-type mice, because of sudden death;
Cx43 localization is also impaired and it is not targeted to the
plasma membrane, resulting in impairment of the function
[17].
The present study reveals a novel function of G-CSF and
presents a new therapeutic insight into arrhythmia. These are
based on our results showing that G-CSF activates the Wnt
signal, and that the Cx43 protein level is sustained during hy-
poxia by G-CSF. Furthermore, the expression levels of Cx43,
cadherin, and b-catenin are all increased by G-CSF, as is their
appropriate localization at the plasma membrane. These re-
sults suggest that G-CSF regulates these protein levels and
their localization, thereby activating their function, and
prompts us to speculate that G-CSF actually possesses the
anti-arrhythmia eﬀects.
In vivo studies indicate an anti-arrhythmia eﬀect on the
acute ischemic heart. Surprisingly, G-CSF eﬃciently decreases
the incidence of lethal ventricular tachycardia in rats with
myocardial infarction. G-CSF clearly decreases the duration
of sustained ventricular tachycardia. These eﬀects of G-CSF
might contribute to the increased survival of rats with acute
myocardial infarction, as reported in a recent study [35], which
only suggests a link between G-CSF and an anti-arrhythmia
eﬀect alone, but does not reveal the precise mechanisms. Based
on other studies using myocardial infarcted rats, their ﬁndings
suggest that G-CSF inhibits cardiomyocytes apoptosis during
the progression of heart failure [7], accelerates angiogenesis
[36], and enhances the attenuation of the inﬂammatory reac-
tion during the acute myocardial infarction [5]. Although those
speculative aspects of G-CSF are not independent, the new ef-
fect of G-CSF revealed by the present study may indicate a
pivotal role for G-CSF in inhibiting arrhythmia by modulating
gap junction components. Therefore, our study may provide a
novel therapeutic indication for the use of G-CSF in patients
with myocardial infarction in order to inhibit lethal arrhyth-
mia in the acute phase.Acknowledgement: This study was supported by a Health and Labor
Sciences Research Grant (H15-PHYSI-001) for Advanced Medical
Technology from the Ministry of Health, Labor, and Welfare of
Japan.
M. Kuwabara et al. / FEBS Letters 581 (2007) 4821–4830 4829References
[1] Alvarez-Dolado, M., Pardal, R., Garcia-Verdugo, J.M., Fike,
J.R., Lee, H.O., Pfeﬀer, K., Lois, C., Morrison, S.J. and Alvarez-
Buylla, A. (2003) Fusion of bone-marrow-derived cells with
Purkinje neurons, cardiomyocytes and hepatocytes. Nature 425,
968–973.
[2] Murry, C.E., Soonpaa, M.H., Reinecke, H., Nakajima, H.,
Nakajima, H.O., Rubart, M., Pasumarthi, K.B., Virag, J.I.,
Bartelmez, S.H., Poppa, V., Bradford, G., Dowell, J.D., Williams,
D.A. and Field, L.J. (2004) Haematopoietic stem cells do not
transdiﬀerentiate into cardiac myocytes in myocardial infarcts.
Nature 428, 664–668.
[3] Balsam, L.B., Wagers, A.J., Christensen, J.L., Koﬁdis, T.,
Weissman, I.L. and Robbins, R.C. (2004) Haematopoietic stem
cells adopt mature haematopoietic fates in ischaemic myocar-
dium. Nature 428, 668–673.
[4] Nygren, J.M., Jovinge, S., Breitbach, M., Sawen, P., Roll, W.,
Hescheler, J., Taneera, J., Fleischmann, B.K. and Jacobsen, S.E.
(2004) Bone marrow-derived hematopoietic cells generate cardio-
myocytes at a low frequency through cell fusion, but not
transdiﬀerentiation. Nat. Med. 10, 494–501.
[5] Minatoguchi, S., Takemura, G., Chen, X.H., Wang, N., Uno, Y.,
Koda, M., Arai, M., Misao, Y., Lu, C., Suzuki, K., Goto, K.,
Komada, A., Takahashi, T., Kosai, K., Fujiwara, T. and
Fujiwara, H. (2004) Acceleration of the healing process and
myocardial regeneration may be important as a mechanism of
improvement of cardiac function and remodeling by postinfarc-
tion granulocyte colony-stimulating factor treatment. Circulation
109, 2572–2580.
[6] Sugano, Y., Anzai, T., Yoshikawa, T., Maekawa, Y., Kohno, T.,
Mahara, K., Naito, K. and Ogawa, S. (2005) Granulocyte colony-
stimulating factor attenuates early ventricular expansion after
experimental myocardial infarction. Cardiovasc. Res. 65, 446–
456.
[7] Harada, M., Qin, Y., Takano, H., Minamino, T., Zou, Y., Toko,
H., Ohtsuka, M., Matsuura, K., Sano, M., Nishi, J., Iwanaga, K.,
Akazawa, H., Kunieda, T., Zhu, W., Hasegawa, H., Kunisada,
K., Nagai, T., Nakaya, H., Yamauchi-Takihara, K. and Komuro,
I. (2005) G-CSF prevents cardiac remodeling after myocardial
infarction by activating the Jak-Stat pathway in cardiomyocytes.
Nat. Med. 11, 305–311.
[8] Lerner, D.L., Yamada, K.A., Schuessler, R.B. and Saﬃtz, J.E.
(2000) Accelerated onset and increased incidence of ventricular
arrhythmias induced by ischemia in Cx43-deﬁcient mice. Circu-
lation 101, 547–552.
[9] Gutstein, D.E., Morley, G.E., Tamaddon, H., Vaidya, D.,
Schneider, M.D., Chen, J., Chien, K.R., Stuhlmann, H. and
Fishman, G.I. (2001) Conduction slowing and sudden arrhythmic
death in mice with cardiac-restricted inactivation of connexin43.
Circ. Res. 88, 333–339.
[10] Gutstein, D.E., Morley, G.E., Vaidya, D., Liu, F., Chen, F.L.,
Stuhlmann, H. and Fishman, G.I. (2001) Heterogeneous
expression of gap junction channels in the heart leads to
conduction defects and ventricular dysfunction. Circulation 104,
1194–1199.
[11] van Rijen, H.V., Eckardt, D., Degen, J., Theis, M., Ott, T.,
Willecke, K., Jongsma, H.J., Opthof, T. and de Bakker, J.M.
(2004) Slow conduction and enhanced anisotropy increase the
propensity for ventricular tachyarrhythmias in adult mice with
induced deletion of connexin43. Circulation 109, 1048–1055.
[12] Ando, M., Katare, R.G., Kakinuma, Y., Zhang, D., Yamasaki,
F., Muramoto, K. and Sato, T. (2005) Eﬀerent vagal nerve
stimulation protects heart against ischemia-induced arrhythmias
by preserving connexin43 protein. Circulation 112, 164–170.
[13] el-Fouly, M.H., Trosko, J.E. and Chang, C.C. (1987) Scrape-
loading and dye transfer. A rapid and simple technique to study
gap junctional intercellular communication. Exp. Cell Res. 168,
422–430.
[14] Musil, L.S., Le, A.C., VanSlyke, J.K. and Roberts, L.M. (2000)
Regulation of connexin degradation as a mechanism to increase
gap junction assembly and function. J. Biol. Chem. 275, 25207–
25215.
[15] Doble, B.W., Chen, Y., Bosc, D.G., Litchﬁeld, D.W. and
Kardami, E. (1996) Fibroblast growth factor-2 decreases meta-bolic coupling and stimulates phosphorylation as well as masking
of connexin43 epitopes in cardiac myocytes. Circ. Res. 79, 647–
658.
[16] Fernandes, R., Girao, H. and Pereira, P. (2004) High glucose
down-regulates intercellular communication in retinal endothelial
cells by enhancing degradation of connexin 43 by a proteasome-
dependent mechanism. J. Biol. Chem. 279, 27219–27224.
[17] Li, J., Patel, V.V., Kostetskii, I., Xiong, Y., Chu, A.F., Jacobson,
J.T., Yu, C., Morley, G.E., Molkentin, J.D. and Radice, G.L.
(2005) Cardiac-speciﬁc loss of N-cadherin leads to alteration in
connexins with conduction slowing and arrhythmogenesis. Circ.
Res. 97, 474–481.
[18] Hertig, C.M., Butz, S., Koch, S., Eppenberger-Eberhardt, M.,
Kemler, R. and Eppenberger, H.M. (1996) N-cadherin in adult rat
cardiomyocytes in culture. II. Spatio-temporal appearance of
proteins involved in cell–cell contact and communication. For-
mation of two distinct N-cadherin/catenin complexes. J. Cell Sci.
109, 11–20.
[19] Fujimoto, K., Nagafuchi, A., Tsukita, S., Kuraoka, A., Oho-
kuma, A. and Shibata, Y. (1997) Dynamics of connexins, E-
cadherin and alpha-catenin on cell membranes during gap
junction formation. J. Cell Sci. 110, 311–322.
[20] Kostin, S., Hein, S., Bauer, E.P. and Schaper, J. (1999)
Spatiotemporal development and distribution of intercellular
junctions in adult rat cardiomyocytes in culture. Circ. Res. 85,
154–167.
[21] Kostin, S. and Schaper, J. (2001) Tissue-speciﬁc patterns of gap
junctions in adult rat atrial and ventricular cardiomyocytes
in vivo and in vitro. Circ. Res. 88, 933–939.
[22] Chen, S., Guttridge, D.C., You, Z., Zhang, Z., Fribley, A., Mayo,
M.W., Kitajewski, J. and Wang, C.Y. (2001) Wnt-1 signaling
inhibits apoptosis by activating beta-catenin/T cell factor-medi-
ated transcription. J. Cell Biol. 152, 87–96.
[23] Sinha, D., Wang, Z., Ruchalski, K.L., Levine, J.S., Krishnan, S.,
Lieberthal, W., Schwartz, J.H. and Borkan, S.C. (2005) Lithium
activates the Wnt and phosphatidylinositol 3-kinase Akt
signaling pathways to promote cell survival in the absence of
soluble survival factors. Am. J. Physiol. Renal Physiol. 288, F703–
F713.
[24] Almeida, M., Han, L., Bellido, T., Manolagas, S.C. and Kousteni,
S. (2005) Wnt proteins prevent apoptosis of both uncommitted
osteoblast progenitors and diﬀerentiated osteoblasts by beta-
catenin-dependent and -independent signaling cascades involving
Src/ERK and phosphatidylinositol 3-kinase/AKT. J. Biol. Chem.
280, 41342–41351.
[25] Li, J., Patel, V.V. and Radice, G.L. (2006) Dysregulation of cell
adhesion proteins and cardiac arrhythmogenesis. Clin. Med. Res.
4, 42–52.
[26] De Groot, J.R. and Coronel, R. (2004) Acute ischemia-induced
gap junctional uncoupling and arrhythmogenesis. Cardiovasc.
Res. 62, 323–334.
[27] Cheng, C.F., Kuo, H.C. and Chien, K.R. (2003) Genetic
modiﬁers of cardiac arrhythmias. Trends Mol. Med., 59–66.
[28] Zhang, Y., Kakinuma, Y., Ando, M., Katare, R.G., Yamasaki,
F., Sugiura, T. and Sato, T. (2006) Acetylcholine inhibits the
hypoxia-induced reduction of connexin43 protein in rat cardio-
myocytes. J. Pharmacol. Sci. 101, 214–222.
[29] Ai, Z., Fischer, A., Spray, D.C., Brown, A.M. and Fishman, G.I.
(2000) Wnt-1 regulation of connexin43 in cardiac myocytes. J.
Clin. Invest. 105, 161–171.
[30] Toyofuku, T., Hong, Z., Kuzuya, T., Tada, M. and Hori, M.
(2000) Wnt/frizzled-2 signaling induces aggregation and adhesion
among cardiac myocytes by increased cadherin-beta-catenin
complex. J. Cell Biol. 150, 225–241.
[31] Fujio, Y., Matsuda, T., Oshima, Y., Maeda, M., Mohri, T., Ito,
T., Takatani, T., Hirata, M., Nakaoka, Y., Kimura, R., Kishim-
oto, T. and Azuma, J. (2004) Signals through gp130 upregulate
Wnt5a and contribute to cell adhesion in cardiac myocytes. FEBS
Lett. 573, 202–206.
[32] Kostin, S., Hein, S., Bauer, E.P. and Schaper, J. (1999) Spatio-
temporal development and distribution of intercellular junctions
in adult rat cardiomyocytes in culture. Circ. Res. 85, 154–167.
[33] Wu, J.C., Tsai, R.Y. and Chung, T.H. (2003) Role of catenins in
the development of gap junctions in rat cardiomyocytes. J. Cell
Biochem. 88, 823–835.
4830 M. Kuwabara et al. / FEBS Letters 581 (2007) 4821–4830[34] Solan, J.L. and Lampe, P.D. (2005) Connexin phosphorylation as
a regulatory event linked to gap junction channel assembly.
Biochim. Biophys. Acta 1711, 154–163.
[35] Kuhlmann, M.T., Kirchhof, P., Klocke, R., Hasib, L., Stypmann,
J., Fabritz, L., Stelljes, M., Tian, W., Zwiener, M., Mueller, M.,
Kienast, J., Breithardt, G. and Nikol, S. (2006) G-CSF/SCF
reduces inducible arrhythmias in the infarcted heart potentiallyvia increased connexin43 expression and arteriogenesis. J. Exp.
Med. 203, 87–97.
[36] Ohki, Y., Heissig, B., Sato, Y., Akiyama, H., Zhu, Z., Hicklin,
D.J., Shimada, K., Ogawa, H., Daida, H., Hattori, K. and
Ohsaka, A. (2005) Granulocyte colony-stimulating factor pro-
motes neovascularization by releasing vascular endothelial growth
factor from neutrophils. FASEB J. 19, 2005–2007.
